1
|
Bistué-Rovira À, Rico LG, Bardina J, Juncà J, Granada I, Bradford JA, Ward MD, Salvia R, Solé F, Petriz J. Persistence of Chronic Lymphocytic Leukemia Stem-like Populations under Simultaneous In Vitro Treatment with Curcumin, Fludarabine, and Ibrutinib: Implications for Therapy Resistance. Int J Mol Sci 2024; 25:1994. [PMID: 38396682 PMCID: PMC10888954 DOI: 10.3390/ijms25041994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 01/11/2024] [Accepted: 01/25/2024] [Indexed: 02/25/2024] Open
Abstract
Leukemic stem cells (LSCs) possess similar characteristics to normal hematopoietic stem cells, including self-renewal capacity, quiescence, ability to initiate leukemia, and drug resistance. These cells play a significant role in leukemia relapse, persisting even after apparent remission. LSCs were first described in 1994 by Lapidot et al. Although they have been extensively studied in acute leukemia, more LSC research is still needed in chronic lymphocytic leukemia (CLL) to understand if reduced apoptosis in mature cells should still be considered as the major cause of this disease. Here, we provide new evidence suggesting the existence of stem-like cell populations in CLL, which may help to understand the disease as well as to develop effective treatments. In this study, we identified a potential leukemic stem cell subpopulation using the tetraploid CLL cell line I83. This subpopulation is characterized by diploid cells that were capable of generating the I83 tetraploid population. Furthermore, we adapted a novel flow cytometry analysis protocol to detect CLL subpopulations with stem cell properties in peripheral blood samples and primary cultures from CLL patients. These cells were identified by their co-expression of CD19 and CD5, characteristic markers of CLL cells. As previously described, increased alkaline phosphatase (ALP) activity is indicative of stemness and pluripotency. Moreover, we used this method to investigate the potential synergistic effect of curcumin in combination with fludarabine and ibrutinib to deplete this subpopulation. Our results confirmed the effectiveness of this ALP-based analysis protocol in detecting and monitoring leukemic stem-like cells in CLL. This analysis also identified limitations in eradicating these populations using in vitro testing. Furthermore, our findings demonstrated that curcumin significantly enhanced the effects of fludarabine and ibrutinib on the leukemic fraction, exhibiting synergistic effects (combination drug index, CDI 0.97 and 0.37, respectively). Our results lend support to the existence of potential stem-like populations in CLL cell lines, and to the idea that curcumin could serve as an effective adjuvant in therapies aimed at eliminating these populations and improving treatment efficacy.
Collapse
Affiliation(s)
- Àngel Bistué-Rovira
- Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), 08193 Cerdanyola del Vallès, Spain;
| | - Laura G. Rico
- Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain; (L.G.R.); (R.S.)
| | - Jorge Bardina
- Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
| | - Jordi Juncà
- MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain; (J.J.); (I.G.); (F.S.)
| | - Isabel Granada
- MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain; (J.J.); (I.G.); (F.S.)
| | - Jolene A. Bradford
- Thermo Fisher Scientific, Fort Collins, CO 80524, USA; (J.A.B.); (M.D.W.)
| | - Michael D. Ward
- Thermo Fisher Scientific, Fort Collins, CO 80524, USA; (J.A.B.); (M.D.W.)
| | - Roser Salvia
- Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain; (L.G.R.); (R.S.)
| | - Francesc Solé
- MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, 08916 Badalona, Spain; (J.J.); (I.G.); (F.S.)
| | - Jordi Petriz
- Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona (UAB), 08916 Badalona, Spain; (L.G.R.); (R.S.)
| |
Collapse
|
2
|
Güell N, Mozas P, Jimenez-Rueda A, Miljkovic M, Juncà J, Sorigue M. Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. Crit Rev Clin Lab Sci 2023; 60:83-100. [PMID: 36066070 DOI: 10.1080/10408363.2022.2114418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The diagnosis of leukemic B-cell lymphoproliferative disorders (B-LPDs) is made by integrating clinical, cytological, cytometric, cytogenetic, and molecular data. This leaves room for differences and inconsistencies between experts. In this study, we examine methodological and conceptual aspects of the flow cytometric classification of leukemic B-LPDs that could explain them. Among methodological aspects, we discuss (1) the different statistical tests used to select and evaluate markers, (2) how these markers are analyzed, (3) how scores are interpreted, (4) different degrees to which diagnostic information is used, and (5) and the impact of differences in study populations. Among conceptual aspects, we discuss (1) challenges to integrating different biological data points, (2) the under examination of the costs of misclassification (false positives and false negatives), and finally, (3) we delve into the impact of the lack of a true diagnostic gold standard and the indirect evidence suggesting poor reproducibility in the diagnosis of leukemic B-LPDs. We then outline current harmonization efforts and our personal approach. We conclude that numerous flow cytometry scores and diagnostic systems are now available; however, as long as the considerations discussed remain unaddressed, external reproducibility and interobserver agreement will not be achieved, and the field will not be able to move forward if a true gold standard is not found.
Collapse
Affiliation(s)
- Nadia Güell
- Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Pablo Mozas
- Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Alba Jimenez-Rueda
- Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain.,Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | | | - Jordi Juncà
- Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Marc Sorigue
- Hematology Laboratory, Unitat de citometria ICO-Badalona (CITICOB), Hospital Germans Trias i Pujol, IJC, LUMN, Universitat Autònoma de Barcelona, Badalona, Spain
| |
Collapse
|
3
|
Rico LG, Salvia R, Juncà J, Ward MD, Bradford JA, Sorigué M, Petriz J. Erythrocyte Lysing Solutions Have a Detrimental Effect in Flow Cytometric Dendritic Cell Detection. Cytometry A 2022; 103:383-391. [PMID: 36214110 DOI: 10.1002/cyto.a.24696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 09/06/2022] [Accepted: 10/06/2022] [Indexed: 11/08/2022]
Abstract
Flow cytometry enumeration of Peripheral Blood Dendritic Cells (PBDCs) is a minimally invasive procedure extremely useful for immunological studies. Numbers of PBDCs vary depending on age, lifestyle, or in pathologies like cancer, leukemia or immunodeficiencies. Conventional methods for PBDC identification by flow cytometry involve red blood cell lysis using either formaldehyde or ammonium chloride based solutions. This specific procedure has been widely reported to cause a detrimental effect as well as an artifactual detection of target populations. Alternatively, minimal sample perturbation assays that avoid the use of erythrolytic solutions with centrifugation steps and preserve the native cellular state are simpler and more robust than conventional methods. In this study, we aimed to evaluate how conventional flow cytometry assays can alter dendritic cell counting when compared with minimal sample perturbation protocols, in terms of absolute cell counting, percentage and Stain Index (SI) of PBDC subsets. We evaluated the use of three different erythrolytic solutions (CyLyse™, OptiLyse C, and Pharm Lyse™) on a series of n = 20 peripheral blood specimens for conventional and plasmacytoid DCs detection as well as for leukocyte and basophil detection. Our results showed a significant reduction of leukocytes and, specifically, of DCs and basophils in terms of absolute number when using erythrolytic solutions. In conclusion, our study shows that PBDC counting is heavily affected when lysing solutions are used, indicating that these stellate-shaped populations appear to be more labile. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Laura G Rico
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Roser Salvia
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Jordi Juncà
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Mike D Ward
- Thermo Fisher Scientific, Eugene, Oregon, USA
| | | | - Marc Sorigué
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Jordi Petriz
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| |
Collapse
|
4
|
Rico LG, de la Calle FR, Salvia R, Ward MD, Bradford JA, Juncà J, Sorigué M, Petriz J. Impact of red blood cell lysing on rare event analysis. Cytometry A 2022; 103:335-346. [PMID: 36069147 DOI: 10.1002/cyto.a.24688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 08/26/2022] [Accepted: 08/30/2022] [Indexed: 11/10/2022]
Abstract
The challenges associated with analyzing rare cells are dependent on a series of factors, which usually require large numbers of cells per sample for successful resolution. Among these is determining the minimum number of total events needed to be acquired as defined by the expected frequency of the target cell population. The choice of markers that identify the target population, as well as the event rate and the number of aborted events/second, will also determine the statistically significant detection of rare cell events. Sample preparation is another important but often overlooked factor in rare cell analysis, and in this study we examine Poisson theory and methods to determine the effect of sample manipulation on rare cell detection. After verifying the applicability of this theory, we have evaluated the potential impact of red cell lysis on rare cell analysis, and how cell rarity can be underestimated or overestimated based on erythrolytic sensitivity or resistance of healthy leukocytes and pathological rare cells. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Laura G Rico
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Fernando Raimúndez de la Calle
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Roser Salvia
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Mike D Ward
- Thermo Fisher Scientific, Eugene, Oregon, USA
| | | | - Jordi Juncà
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Marc Sorigué
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| | - Jordi Petriz
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP) , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain
| |
Collapse
|
5
|
Sorigue M, Juncà J, Zamora L. On the distinction between acute leukemia with mutated NPM1 and acute promyelocytic leukemia by flow cytometry. Int J Lab Hematol 2022; 44:e187-e190. [PMID: 35916217 DOI: 10.1111/ijlh.13530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Revised: 01/19/2021] [Accepted: 02/23/2021] [Indexed: 12/01/2022]
Affiliation(s)
- Marc Sorigue
- Hematology Laboratory, Hospital Germans Trias i Pujol (ICO Badalona), Barcelona, Spain
| | - Jordi Juncà
- Hematology Laboratory, Hospital Germans Trias i Pujol (ICO Badalona), Barcelona, Spain
| | - Lurdes Zamora
- Hematology Laboratory, Hospital Germans Trias i Pujol (ICO Badalona), Barcelona, Spain
| |
Collapse
|
6
|
Espasa A, Tapia G, Vergara S, Raya M, Juncà J, Sorigue M. Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma. Scand J Clin Lab Invest 2021; 81:413-417. [PMID: 34057378 DOI: 10.1080/00365513.2021.1929446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Flow cytometry is a useful ancillary tool for the diagnosis of nodal B cell lymphomas. Well-established antigens have diagnostic limitations. This study aimed to assess the expression of CD71, CD81, CD44 and CD39 by flow cytometry in B cell lymphomas. Expression of these 4 antigens was queried in 185 samples with a diagnosis of a B cell lymphoma according to a histological examination of the lymph node and the World Health Organization (WHO) classification (follicular lymphoma [FL, n = 96], diffuse large B cell lymphoma/High grade B cell lymphoma [DLBCL/HGBH, n = 48], marginal zone lymphoma/lymphoplasmacytic lymphoma [MZL/LPL, n = 14], chronic lymphocytic leukemia/small lymphocytic lymphoma [CLL, n = 10], mantle cell lymphoma [MCL, n = 11], Burkitt lymphoma [BL, n = 4] and other [n = 2]). CD81 was bright and CD44 was dim in germinal center-derived malignancies, particularly aggressive lymphomas (BL and CD10-positive DLBCL/HGBL). CD81 was very dim in CLL. CD71 was bright in aggressive lymphomas (DLBCL/HGBL and BL). CD39 was bright in CD10-negative DLBCL. CD71 appeared valuable in the differential diagnosis between indolent and aggressive lymphomas, CD39 between CD10-negative DLBCL and MZL/LPL and CD81 between MCL and CLL. To conclude, we report the expression of CD71, CD81, CD44 and CD39 by FC in B cell lymphomas. Further studies will have to determine the value they add to specific FC panels.
Collapse
Affiliation(s)
- Andrea Espasa
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain
| | - Gustavo Tapia
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain.,Department of Pathology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Sara Vergara
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain
| | - Minerva Raya
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain
| | - Jordi Juncà
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain
| | - Marc Sorigue
- Hematology Laboratory,ICO-Hospital Germans Trias i Pujol, LUMN, IJC-Functional Cytomics unit, UAB, Badalona, Spain
| |
Collapse
|
7
|
Rico LG, Aguilar Hernández A, Ward MD, Bradford JA, Juncà J, Rosell R, Petriz J. Unmasking the expression of PD-L1 in Myeloid Derived Suppressor Cells: A case study in lung cancer to discover new drugs with specific on-target efficacy. Transl Oncol 2020; 14:100969. [PMID: 33395749 PMCID: PMC7723799 DOI: 10.1016/j.tranon.2020.100969] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 11/13/2020] [Accepted: 11/20/2020] [Indexed: 11/18/2022] Open
Affiliation(s)
- Laura G Rico
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras, IJC, Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Barcelona, Catalonia, 08916, Spain
| | | | | | | | - Jordi Juncà
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol (HGTiP), Badalona, Spain
| | - Rafael Rosell
- Quirón Dexeus University Hospital, Dr Rosell Oncology Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol (HGTiP), Badalona, Spain.
| | - Jordi Petriz
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras, IJC, Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Barcelona, Catalonia, 08916, Spain.
| |
Collapse
|
8
|
Tort‐Merino A, Balasa M, Olives J, Contador J, Falgàs N, Castellví M, Juncà J, Borrejo‐Écija S, Bosch B, Fernández‐Villullas G, Ramos‐Campoy O, Antonell A, Rami L, Sanchez‐Valle R, Lladó A. Distinct neuropsychological presentation and progression between early‐ and late‐onset Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.036809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Adrià Tort‐Merino
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Mircea Balasa
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | | | - José Contador
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS Barcelona Spain
| | - Neus Falgàs
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Magdalena Castellví
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS Barcelona Spain
| | - Jordi Juncà
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS Barcelona Spain
| | | | - Beatriz Bosch
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Guadalupe Fernández‐Villullas
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Oscar Ramos‐Campoy
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Anna Antonell
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic, Fundació Clínic per a la Recerca Biomèdica, IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Lorena Rami
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS Barcelona Spain
| | | | - Albert Lladó
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic of Barcelona, IDIBAPS Barcelona Spain
| |
Collapse
|
9
|
Contador J, Tort‐Merino A, Balasa M, Falgàs N, Olives J, Castellví M, Juncà J, Borrego‐Écija S, Bosch B, Fernández‐Villullas G, Ramos‐Campoy O, Antonell A, Sanchez‐Valle R, Lladó A. Four years’ experience in an early‐onset dementia clinic in Barcelona. Alzheimers Dement 2020. [DOI: 10.1002/alz.037911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- José Contador
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Adrià Tort‐Merino
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Mircea Balasa
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Neus Falgàs
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | | | - Magdalena Castellví
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Jordi Juncà
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Sergi Borrego‐Écija
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Beatriz Bosch
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Guadalupe Fernández‐Villullas
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Oscar Ramos‐Campoy
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Anna Antonell
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | | | - Albert Lladó
- Alzheimer’s Disease and Other Cognitive Disorders Unit Hospital Clínic Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| |
Collapse
|
10
|
Sala‐Llonch R, Contador J, Pérez‐Millan A, Falgàs N, Ruiz‐Peris M, Tort‐Merino A, Balasa M, Olives J, Castellví M, Juncà J, Borrego‐Écija S, Bosch B, Fernández‐Villullas G, Ramos‐Campoy O, Antonell A, Sanchez‐Valle R, Lladó A. Functional network alterations in early‐onset Alzheimer’s disease studied with resting‐state fMRI. Alzheimers Dement 2020. [DOI: 10.1002/alz.043307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - José Contador
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Agnés Pérez‐Millan
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Neus Falgàs
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | | | - Adrià Tort‐Merino
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Mircea Balasa
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | | | - Magdalena Castellví
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Jordi Juncà
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic of Barcelona IDIBAPS Barcelona Spain
| | - Sergi Borrego‐Écija
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Beatriz Bosch
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Guadalupe Fernández‐Villullas
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Oscar Ramos‐Campoy
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Anna Antonell
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| | - Raquel Sanchez‐Valle
- Universitat de Barcelona Barcelona Spain
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
| | - Albert Lladó
- Alzheimer’s Disease and Other Cognitive Disorders Unit. Hospital Clínic. Fundació Clínic per a la Recerca Biomèdica IDIBAPS Universitat de Barcelona Barcelona Spain
| |
Collapse
|
11
|
Espasa A, Torrents S, Morales‐Indiano C, Rico LG, Bardina J, Ancochea A, Bistué‐Rovira À, Linio R, Raya M, Vergara S, Juncà J, Grifols J, Petriz J, Soria M, Sorigue M. Diagnostic performance of the ClearLLab 10C B cell tube. Cytometry 2020; 100:519-530. [DOI: 10.1002/cyto.b.21955] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 09/03/2020] [Accepted: 09/07/2020] [Indexed: 12/20/2022]
Affiliation(s)
- Andrea Espasa
- Hematology Laboratory Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Functional cytomics‐IJC, Universitat Autònoma de Barcelona Badalona Spain
| | | | - Cristian Morales‐Indiano
- Clinical Laboratory ICS‐Metropolitana Nord, Core‐Hematology Department Hospital Germans Trias i Pujol Badalona Spain
| | - Laura G. Rico
- Functional Cytomics, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona Barcelona Spain
| | - Jorge Bardina
- Functional Cytomics, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona Barcelona Spain
| | - Agueda Ancochea
- Banc de Sang i Teixits Hospital Germans Trias i Pujol Badalona Spain
| | - Àngel Bistué‐Rovira
- Functional Cytomics, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona Barcelona Spain
| | - Rosa Linio
- Banc de Sang i Teixits Hospital Germans Trias i Pujol Badalona Spain
| | - Minerva Raya
- Hematology Laboratory Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Functional cytomics‐IJC, Universitat Autònoma de Barcelona Badalona Spain
| | - Sara Vergara
- Hematology Laboratory Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Functional cytomics‐IJC, Universitat Autònoma de Barcelona Badalona Spain
| | - Jordi Juncà
- Hematology Laboratory Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Functional cytomics‐IJC, Universitat Autònoma de Barcelona Badalona Spain
- Functional Cytomics, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona Barcelona Spain
| | | | - Jordi Petriz
- Functional Cytomics, Josep Carreras Leukaemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona Barcelona Spain
| | | | - Marc Sorigue
- Hematology Laboratory Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Functional cytomics‐IJC, Universitat Autònoma de Barcelona Badalona Spain
| |
Collapse
|
12
|
Bardina J, Rico LG, Ward MD, Bradford JA, Juncà J, Petriz J. Flow Cytometric Quantification of Granulocytic Alkaline Phosphatase Activity in Unlysed Whole Blood. ACTA ACUST UNITED AC 2020; 93:e76. [PMID: 32543779 DOI: 10.1002/cpcy.76] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Translational research has improved the diagnosis and follow-up of hematological diseases and malignancies. However, some classical diagnostics used for research and clinical practice that have remain practically unchanged for decades may be better addressed through advances in flow cytometry technology, whereby more precise measurements may be implemented in a straightforward manner. The current method for semiquantitative analysis of granulocytic alkaline phosphatase (GAP) activity is still based on observer-dependent color-intensity classification. Here, we describe a novel strategy for flow cytometric quantification of GAP activity in which staining and analytical flow cytometry facilitate the detection and quantification of subpopulations of leukocytes with different GAP activities. Our experiments demonstrate the potential of flow cytometry as a simple and highly sensitive approach for measuring GAP activity in unlysed whole blood. Notably, a comparison of flow cytometry and enzyme cytochemistry techniques showed that enzyme activity scores were not similar, indicating that results needs to be interpreted with caution, given that the enzyme-substrate binding affinities may differ, as well as the subjective evaluation of the intensity of the precipitated dye. © 2020 Wiley Periodicals LLC. Basic Protocol: Protocol preparation, sample acquisition, and gating strategy for flow cytometric identification of alkaline phosphatase activity in granulocytes from whole blood samples Support Protocol 1: Sample preparation for granulocyte alkaline phosphatase determination by flow cytometry using no-lyse no-wash methods Support Protocol 2: Data analysis and formula to calculate the GAP score.
Collapse
Affiliation(s)
- Jorge Bardina
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Catalonia, Spain
| | - Laura G Rico
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Catalonia, Spain
| | | | | | - Jordi Juncà
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Catalonia, Spain.,Institut Català d'Oncologia, Hospital Germans Trias i Pujol (HGTiP), Badalona, Catalonia, Spain
| | - Jordi Petriz
- Functional Cytomics Group, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Institut Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, UAB, Badalona, Catalonia, Spain
| |
Collapse
|
13
|
Gener G, Espasa A, Raya M, Vergara S, Juncà J, Sorigue M. Brief communication: Distribution of bone marrow cell subsets and hemodilution in patients with acute leukemia. Int J Lab Hematol 2020; 42:e192-e195. [PMID: 32449827 DOI: 10.1111/ijlh.13243] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 04/25/2020] [Accepted: 05/04/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Georgina Gener
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Andrea Espasa
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Minerva Raya
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Sara Vergara
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Jordi Juncà
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Marc Sorigue
- Hematology Laboratory, Institut Català d'Oncologia, Functional cytomics-IJC, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| |
Collapse
|
14
|
Genescà E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, González-Gil C, Zamora L, Ramírez JL, Díaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Monsalvo S, Novo A, Cervera M, García-Guiñon A, Juncà J, Ciudad J, Orfao A, Ribera JM. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. Haematologica 2019; 105:e294-e297. [PMID: 31537688 DOI: 10.3324/haematol.2019.225078] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- Eulàlia Genescà
- Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Mireia Morgades
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Pau Montesinos
- Hospital Universitari i Politècnic La Fe & CIBERONC, Instituto Carlos III, Madrid
| | - Pere Barba
- Clinical Hematology Service, Hospital Universitari de la Vall d'Hebron, Barcelona
| | - Cristina Gil
- Clinical Hematology Service, Hospital General de Alicante, Alicante
| | - Ramon Guàrdia
- Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona
| | | | | | | | - Susana Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Jordi Ribera
- Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | | | - Celia González-Gil
- Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Lurdes Zamora
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - José-Luís Ramírez
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Marina Díaz-Beya
- Clinical Hematology Service, Hospital Clínic de Barcelona, Barcelona
| | - Santiago Mercadal
- Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del Llobregat
| | | | - Antònia Cladera
- Clinical Hematology Service, Hospital Son Llàtzer, Palma de Mallorca
| | - Mar Tormo
- Clinical Hematology Service, Hospital Clínico de Valencia, Valencia
| | - Arancha Bermúdez
- Clinical Hematology Service, Hospital Marqués de Valdecilla, Santander
| | | | - Pilar Martínez
- Clinical Hematology Service, Hospital 12 de Octubre, Madrid
| | - María-Luz Amigo
- Clinical Hematology Service, Hospital Morales Meseguer, Murcia
| | - Silvia Monsalvo
- Clinical Hematology Service, Hospital Gregorio Marañón, Madrid
| | - Andrés Novo
- Clinical Hematology Service, Hospital Son Espases, Palma de Mallorca
| | - Marta Cervera
- Clinical Hematology Service, Hospital Joan XXIII, Tarragona
| | | | - Jordi Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| | - Juana Ciudad
- Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Hospital Clínico Universitario de Salamanca, Instituto Bio-Sanitario de Salamanca, CIBERONC Salamanca, Spain
| | - Alberto Orfao
- Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Hospital Clínico Universitario de Salamanca, Instituto Bio-Sanitario de Salamanca, CIBERONC Salamanca, Spain
| | - Josep-Maria Ribera
- Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona.,Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona
| |
Collapse
|
15
|
Rico LG, Juncà J, Ward MD, Bradford J, Petriz J. Correction: Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells? Oncotarget 2019; 10:2335. [PMID: 31040923 PMCID: PMC6481347 DOI: 10.18632/oncotarget.26816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Laura G Rico
- Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Spain
| | - Jordi Juncà
- Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Spain
| | - Mike D Ward
- Thermo Fisher Scientific, Eugene, Oregon, USA
| | | | - Jordi Petriz
- Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Spain
| |
Collapse
|
16
|
Sorigue M, Raya M, Vergara S, Sarrate E, Orna E, Juncà J. Refining the Limits of Borderline Lymphoproliferative Disorders. Cytometry 2018; 96:351-358. [DOI: 10.1002/cyto.b.21760] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2018] [Revised: 10/25/2018] [Accepted: 11/10/2018] [Indexed: 12/30/2022]
Affiliation(s)
- Marc Sorigue
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| | - Minerva Raya
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| | - Sara Vergara
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| | - Edurne Sarrate
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| | - Elisa Orna
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| | - Jordi Juncà
- Flow Cytometry Unit, Hematology Laboratory, ICO‐Hospital Germans Trias i Pujol, Institut de Recerca Josep CarrerasUniversitat Autònoma de Barcelona Badalona Spain
| |
Collapse
|
17
|
Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol 2018; 11:96. [PMID: 30041662 PMCID: PMC6057006 DOI: 10.1186/s13045-018-0639-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 07/09/2018] [Indexed: 01/14/2023] Open
Abstract
Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- E Genescà
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain. .,ALL Research Group, Josep Carreras Leukaemia Research Institute (IJC), Camí de les Escoles s/n. Edifici IJC, 08916, Badalona, Spain.
| | - A Lazarenkov
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - M Morgades
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - G Berbis
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - N Ruíz-Xivillé
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Gómez-Marzo
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Ribera
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - A González-Pérez
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain
| | - S Mercadal
- Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del LLobregat, Barcelona, Spain
| | - R Guardia
- Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona, Spain
| | - M T Artola
- Clinical Hematology Service, Hospital Universitario de Donostia, Donostia, Spain
| | - M J Moreno
- Clinical Hematology Service, Hospital Vírgen de la Victoria, Málaga, Spain
| | - J Martínez-López
- Hematology Department, Hospital 12 de Octubre, CNIO, Universidad Complutense, Madrid, Spain
| | - L Zamora
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - P Barba
- Clinical Hematology Service, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain
| | - C Gil
- Clinical Hematology Service, Hospital General de Alicante, Alicante, Spain
| | - M Tormo
- Clinical Hematology Service, Hospital Clínico de Valencia, Valencia, Spain
| | - A Cladera
- Clinical Hematology Service, Hospital Son Llàtzer, Palma, Spain
| | - A Novo
- Clinical Hematology Service, Hospital Son Espases, Palma, Spain
| | - M Pratcorona
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J Nomdedeu
- Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J González-Campos
- Clinical Hematology Service, Hospital Vírgen del Rocío, Sevilla, Spain
| | - M Almeida
- Banco Nacional de ADN Carlos III, Universidad de Salamanca, Salamanca, Spain
| | - J Cervera
- Biobanco de la Fe, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain
| | - P Montesinos
- Clinical Hematology Service, Hospital La Fe, Valencia, Spain
| | - M Batlle
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - S Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - J Esteve
- Clinical Hematology Service, Hospital Clínic de Barcelona, Barcelona, Spain
| | - E Feliu
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - F Solé
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - A Orfao
- Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) (CIC), Hospital Clínico Universitario de Salamanca (HUS), Instituto Bio-Sanitario de Salamanca (IBSAL), CIBERONC, Salamanca, Spain
| | - J M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| |
Collapse
|
18
|
Affiliation(s)
- Laura G Rico
- Josep Carreras Leukaemia Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona (Barcelona), Spain
| | - Jordi Juncà
- Josep Carreras Leukaemia Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona (Barcelona), Spain
| | - Mike D Ward
- Flow Cytometry Systems, Thermo Fisher Scientific, Eugene, Oregon, United States
| | - Jolene Bradford
- Flow Cytometry Systems, Thermo Fisher Scientific, Eugene, Oregon, United States
| | - Jordi Petriz
- Josep Carreras Leukaemia Research Institute (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona (Barcelona), Spain
| |
Collapse
|
19
|
Sorigue M, Juncà J. Reply to Foley et al., "Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?". Cancer Genet 2017; 220:77. [PMID: 29195903 DOI: 10.1016/j.cancergen.2017.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Accepted: 11/07/2017] [Indexed: 10/18/2022]
Affiliation(s)
- Marc Sorigue
- Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Josep Carreras Leukemia Research Institute, Badalona, Spain.
| | - Jordi Juncà
- Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Josep Carreras Leukemia Research Institute, Badalona, Spain
| |
Collapse
|
20
|
Sanvisens A, Zuluaga P, Pineda M, Fuster D, Bolao F, Juncà J, Tor J, Muga R. Folate deficiency in patients seeking treatment of alcohol use disorder. Drug Alcohol Depend 2017; 180:417-422. [PMID: 28988003 DOI: 10.1016/j.drugalcdep.2017.08.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2017] [Revised: 08/28/2017] [Accepted: 08/30/2017] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Nutritional deficiency is frequent in patients with an alcohol use disorder (AUD). We aimed to analyze serum and erythrocyte folate deficiency in a case series of patients that initiated treatment of AUD. PATIENTS AND METHODS A cross-sectional study in patients admitted for detoxification between 2007 and 2015 was performed. Sociodemographic characteristics, history of alcohol consumption, type of alcohol, and medical co-morbidity were assessed at admission. Blood samples for biochemistry and hematological parameters were collected at admission. Logistic regression models were used to establish predictors of folate deficiency. RESULTS 211 patients (79.1% men) were eligible; age at admission was 46 years [IQR:40-51], and the amount of alcohol consumption was of 160g/day [IQR:120-200]. Thirty four percent of patients had macrocytosis (MCV>100fL), 12.8% had anemia, 23% of cases presented with serum folate deficiency and 7% presented with erythrocyte folate deficiency. Most (69%) of the patients with serum folate deficiency had normal erythrocyte folate levels. In univariate analysis, macrocytosis (OR=3.4, 95%CI:1.7-6.6), alcohol-related liver disease (ARLD) (OR=2.5, 95%CI:1.0-6.1) and drinking alcoholic beverages other than beer (OR=3.3, 95%CI:1.5-7.3) were associated with folate deficiency. However, only macrocytosis was significantly associated with serum folate deficiency in multivariate analysis (OR=3.1, 95%CI:1.1-8.9). Macrocytosis (P<0.001), ARLD (P=0.01) and the type of alcohol consumption (P<0.001) were factors associated with erythrocyte folate deficiency in univariate analysis. In multivariate analysis only macrocytosis remained significantly associated to erythrocyte folate deficiency (P=0.037). CONCLUSION Folate deficiency is a relatively frequent finding in contemporary, middle-aged patients with AUD, and macrocytosis is significantly associated with the deficiency.
Collapse
Affiliation(s)
- Arantza Sanvisens
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Paola Zuluaga
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Miriam Pineda
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Daniel Fuster
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Ferran Bolao
- Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Universitat de Barcelona, Spain
| | - Jordi Juncà
- Department of Hematology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Jordi Tor
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Robert Muga
- Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
| |
Collapse
|
21
|
Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM. Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. Genes Chromosomes Cancer 2017; 56:810-820. [PMID: 28758283 DOI: 10.1002/gcc.22486] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 07/22/2017] [Accepted: 07/22/2017] [Indexed: 12/11/2022] Open
Abstract
The outcome of relapsed adult acute lymphoblastic leukemia (ALL) remains dismal despite new therapeutic approaches. Previous studies analyzing relapse samples have shown a high degree of heterogeneity regarding gene alterations without an evident relapse signature. Bone marrow or peripheral blood samples from 31 adult B-cell precursor ALL patients at first relapse, and 21 paired diagnostic samples were analyzed by multiplex ligation probe-dependent amplification (MLPA). Nineteen paired diagnostic and relapse samples of these 21 patients were also analyzed by SNP arrays. A trend to acquire homozygous CDKN2A/B deletions and a significant increase in the number of copy number alterations (CNA) was observed from diagnosis to first relapse. Evolution from an ancestral clone was the main pattern of clonal evolution. Relapse samples were extremely heterogeneous regarding CNA frequencies. However, CDKN2A/B, PAX5, ETV6, ATM, IKZF1, VPREB1, and TP53 deletions and duplications of 1q, 8q, 17q, 21, X/Y PAR1, and Xp were frequently detected at relapse. Duplications of genes involved in cell proliferation, drug resistance and stem cell homeostasis regulation, as well as deletions of KDM6A and STAG2 genes emerged as specific alterations at relapse. Genomics of relapsed adult B-cell precursor ALL is highly heterogeneous, although some recurrent lesions involved in essential pathways deregulation were frequently observed. Selective and simultaneous targeting of these deregulated pathways may improve the results of current salvage therapies.
Collapse
Affiliation(s)
- Jordi Ribera
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Lurdes Zamora
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Mireia Morgades
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Mar Mallo
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Neus Solanes
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Montserrat Batlle
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Susana Vives
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Isabel Granada
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Jordi Juncà
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Roberto Malinverni
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Eulàlia Genescà
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Ramon Guàrdia
- Catalan Institute of Oncology-Josep Trueta, Girona, Spain
| | - Santiago Mercadal
- Catalan Institute of Oncology-Duran i Reynals, L'Hospitalet de Llobregat, Spain
| | - Lourdes Escoda
- Catalan Institute of Oncology-Joan XXIII, Tarragona, Spain
| | | | | | - Jordi Esteve
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Clinic Hospital, Barcelona, Spain
| | - Marta Pratcorona
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Sant Pau Hospital, Barcelona, Spain
| | | | - Francesc Solé
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
| | - Evarist Feliu
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| | - Josep-Maria Ribera
- Josep Carreras Leukemia Research Institute (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
- Catalan Institute of Oncology-Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
22
|
Sorigue M, Juncà J, Orna E, Romanic N, Sarrate E, Castellvi J, Soler M, Rodríguez-Hernandez I, Feliu E, Ruiz S. Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. J Thromb Thrombolysis 2017; 44:63-66. [PMID: 28447244 DOI: 10.1007/s11239-017-1502-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder associated with increased risk for thrombosis and reduced life expectancy. Retinal vein occlusion (RVO) is a frequent cause of vision loss but its relationship with PNH has not been studied systematically. Patients followed up for RVO in our ophthalmology department were screened for the presence of a PNH clone in peripheral blood by means of flow cytometry. The presence of other well-documented risk factors for RVO was also analyzed. In a series of 110 patients (54 males, median age of 67) we found no evidence of PNH. Most patients (97/110) had cardiovascular risk factors and/or hyperhomocysteinemia (67/110). Inherited thrombophilias were rare (three confirmed cases). Therefore, PNH does not appear to play a role in the development of RVO. However, this finding does not necessarily apply to young patients and/or those with no conventional risk factors for RVO, due to the low number of patients in these subgroups in our population.
Collapse
Affiliation(s)
- Marc Sorigue
- Hematology Laboratory (Division of Thrombosis and Hemostasis), ICO-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Ctra. Canyet s/n, 08916, Badalona, Spain.
| | - Jordi Juncà
- Hematology Laboratory, ICO-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Elisa Orna
- Hematology Laboratory, ICO-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Nevena Romanic
- Department of Ophthalmology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Edurne Sarrate
- Department of Hematology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Jordi Castellvi
- Department of Ophthalmology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Montse Soler
- Department of Ophthalmology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Ines Rodríguez-Hernandez
- Hematology Laboratory, ICO-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Evarist Feliu
- Hematology Laboratory, ICO-Badalona, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Susana Ruiz
- Department of Ophthalmology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| |
Collapse
|
23
|
Ferrà C, Xicoy B, Castillo N, Morgades M, Juncà J, Andreo F, Millá F, Feliu E, Ribera JM. Usefulness of bronchoalveolar lavage and flow cytometry in patients with hematological malignancies and respiratory failure. Med Clin (Barc) 2017; 148:297-302. [PMID: 28143650 DOI: 10.1016/j.medcli.2016.10.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 10/19/2016] [Accepted: 10/20/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND OBJECTIVES Strategies to improve the efficiency of bronchoalveolar lavage (BAL) are needed. We conducted a study to establish the diagnostic value of BAL in patients with hematological malignancies and pulmonary infiltrates. PATIENTS AND METHODS The correlation of cytologic and flow cytometric study of BAL with the microbiological findings and the clinical evolution was determined. RESULTS Seventy BAL were performed and flow cytometric study was analyzed in 23 of them. Fifty-three patients did not present any adverse event attributable to BAL. Anti-infectious therapy was modified in 64 (91%) patients. T lymphocyte count >0.3×109/l in peripheral blood was associated with longer OS at 3 years (53 vs. 22%, p=.009). Higher CD4 (>20/μL) and CD8 (>35/μL) lymphocyte counts in the BAL were associated with a longer OS at 3 years: 82 vs. 21% (p=.030) and 80 vs. 23% (p=.059). CONCLUSIONS Our study confirms the clinical value of BAL for treatment decision making in patients with hematological malignancies and acute respiratory failure.
Collapse
Affiliation(s)
- Christelle Ferrà
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España; Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España
| | - Blanca Xicoy
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España; Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España.
| | - Nerea Castillo
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España
| | - Mireia Morgades
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España
| | - Jordi Juncà
- Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España
| | - Felipe Andreo
- Servicio de Neumología, Hospital Germans Trias i Pujol, Badalona, España
| | - Fuensanta Millá
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España; Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España
| | - Evarist Feliu
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España; Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España
| | - Josep-María Ribera
- Servicio de Hematología, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, España; Instituto de Investigación contra la Leucemia Josep Carreras, Badalona, Universitat Autònoma de Barcelona, Barcelona, España
| |
Collapse
|
24
|
Sorigue M, Juncà J, Sarrate E, Grau J. Expression of CD43 in chronic lymphoproliferative leukemias. Cytometry B Clin Cytom 2017; 94:136-142. [PMID: 28073173 DOI: 10.1002/cyto.b.21509] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Revised: 12/27/2016] [Accepted: 01/06/2017] [Indexed: 01/25/2023]
Abstract
BACKGROUND CD43 has been used on histological samples for the differential diagnosis of lymphoproliferative disorders but there is scarce data on its use by flow cytometry (FC). We set out to characterize the expression of CD43 by FC in B-cell lymphoproliferative disorders and to determine its possible role in the differential diagnosis of these malignancies. METHODS We analyzed the expression of CD43 in clonal B-cell lymphoproliferative disorders with exclusive peripheral blood and/or bone marrow involvement based on their Moreau chronic lymphocytic leukemia (CLL) score with particular emphasis on Moreau CLL score 3 (MS3) cases, which often present a diagnostic challenge. The cohort included 433 CLL (score 4-5), 34 MS3 and 166 lymphoproliferative disorders with lower scores. RESULTS Generally, the higher the Moreau CLL score, the higher CD43-positivity (425/443 [96%] for CLL, 23/34 [67%] for MS3 and 18/166 [11%] for cases with lower scores). MS3 cases constituted 5.4% of all cases and were more frequently CD5, CD200, CD43-positive and had del(q13) than score 0-2 cases. Among MS3 cases, del(13q) cases were predominantly CD43-positive (12/13). CONCLUSIONS The frequency of CD43-positivity increases sharply with the Moreau score. MS3 cases seem to include both CLL and non-CLL lymphoproliferative disorders and CD43 could aid in the differential diagnosis between the two. However, studies analyzing the correlation between CD43 expression and the underlying biologic changes of these cases are warranted. © 2017 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Marc Sorigue
- Department of Laboratory Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Jordi Juncà
- Department of Laboratory Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Edurne Sarrate
- Department of Laboratory Hematology, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | - Javier Grau
- Department of Laboratory Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain
| |
Collapse
|
25
|
Martín-Alcolea M, Rodríguez-Hernández I, Aldea M, Rosas I, Juncà J, Granada ML. Chronic proton pump inhibition therapy in the diagnostic accuracy of serum pepsinogen I and gastrin concentrations to identify pernicious anaemia. Clin Biochem 2017; 50:481-484. [PMID: 28109748 DOI: 10.1016/j.clinbiochem.2017.01.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 01/17/2017] [Accepted: 01/17/2017] [Indexed: 12/17/2022]
Abstract
BACKGROUND Chronic use of proton pump inhibitors (PPIs) leads to increases in gastrin and pepsinogen-I serum concentrations. AIM To asses if chronic treatment with PPIs has an effect on serum gastrin and pepsinogen-I concentrations for the diagnosis of pernicious anaemia (PA). MATERIALS AND METHODS Serum gastrin and pepsinogen-I were measured in 38 patients with PA and 74 without PA (controls); 17/38 PA patients and 36/74 controls were treated with PPIs. Receiver Operating Curves (ROC) were used to compare diagnostic accuracy of gastrin and pepsinogen-I for PA in patients under chronic treatment with PPIs and in untreated patients. RESULTS PPI treatment increased pepsinogen-I in patients and in controls, while gastrin increased only in controls. In untreated patients, a pepsinogen-I <8.3ng/mL had 95.2% sensitivity and 100% specificity, whereas a gastrin >115pg/mL had 100% sensitivity and 92.11% specificity for PA diagnosis. In PPI-treated patients, a pepsinogen I<24.1ng/mL had a lower sensitivity (82.4%) but retained 100% specificity, however the best cut-off point for gastrin, 610pg/mL, had a very low sensitivity (58%). CONCLUSIONS PPI chronic treatment decreased the diagnostic accuracy for the studied biomarkers, particularly of gastrin. In PPI-treated patients, serum pepsinogen-I concentrations >24.1ng/mL allowed rejecting a PA diagnosis with 100% specificity.
Collapse
Affiliation(s)
- Mariam Martín-Alcolea
- Department of Clinical Biochemistry, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain
| | - Inés Rodríguez-Hernández
- Haematology-Laboratory, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain
| | - Marta Aldea
- Department of Clinical Biochemistry, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain
| | - Irene Rosas
- Department of Clinical Biochemistry, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain
| | - Jordi Juncà
- Haematology-Laboratory, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain
| | - Maria Luisa Granada
- Department of Clinical Biochemistry, Hospital "Germans Trias i Pujol", Universitat Autonoma of Barcelona, Ctra Canyet s/n., 08916 Badalona, Barcelona, Spain.
| |
Collapse
|
26
|
Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M. Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes Cancer 2016; 56:243-252. [PMID: 27750403 DOI: 10.1002/gcc.22430] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 10/13/2016] [Accepted: 10/13/2016] [Indexed: 02/06/2023] Open
Abstract
Leukemia cell lines have been widely used in the hematology field to unravel mechanistic insights and to test new therapeutic strategies. Myelodysplastic syndromes (MDS) comprise a heterogeneous group of diseases that are characterized by ineffective hematopoiesis and frequent progress to acute myeloid leukemia (AML). A few cell lines have been established from MDS patients after progression to AML but their characterization is incomplete. Here we provide a detailed description of the immunophenotypic profile of the MDS-derived cell lines SKK-1, SKM-1, F-36P; and MOLM-13. Specifically, we analyzed a comprehensive panel of markers that are currently applied in the diagnostic routine for myeloid disorders. To provide high-resolution genetic data comprising copy number alterations and losses of heterozygosity we performed whole genome single nucleotide polymorphism-based arrays and included the cell line OHN-GM that harbors the frequent chromosome arm 5q deletion. Furthermore, we assessed the mutational status of 83 disease-relevant genes. Our results provide a resource to the MDS and AML field that allows researchers to choose the best-matching cell line for their functional studies. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Anna Palau
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| | - Mar Mallo
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| | - Laura Palomo
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| | - Ines Rodríguez-Hernández
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Jeannine Diesch
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| | - Diana Campos
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Isabel Granada
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Jordi Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Hans G Drexler
- Department of Human and Animal Cell Lines, Leibniz-Institute DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
| | - Francesc Solé
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| | - Marcus Buschbeck
- Josep Carreras Leukaemia Research Institute, Campus ICO - Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
27
|
Juncà J, Garcia O, Garcia-Caro M, Vila J, Zamora L, Cabezón M, Alonso E, de la Banda E, Rodríguez-Hernández I, Ribera JM, Millá F. CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia. Ann Hematol 2016; 95:1949-1954. [PMID: 27595757 DOI: 10.1007/s00277-016-2811-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 08/24/2016] [Indexed: 10/21/2022]
Abstract
CD34 positivity has been considered as an adverse prognostic factor in acute myeloid leukemia (AML). Although nucleophosmin 1-mutated (NPM1m) AML is usually CD34 negative, this marker may be expressed at diagnosis or acquired at relapse in a variable number of cases. Our objective was to ascertain if CD34 expression has any influence on the general outcome of this form of acute leukemia. Analysis of clinical outcome (complete remissions, relapses, disease-free survival, and overall survival) was performed depending on the degree of expression of CD34 determined by flow cytometry, in 67 adult patients with NPM1m AML. CD34 expression did not have any influence on the variables analyzed whatever the percentage of blasts expressing this marker. In contrast to other forms of AML, CD34 expression is not an unfavorable prognostic factor in NPM1m AML, neither at diagnosis nor at relapse.
Collapse
Affiliation(s)
- Jordi Juncà
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain.
| | - Olga Garcia
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Montse Garcia-Caro
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Jordi Vila
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Lurdes Zamora
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Marta Cabezón
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Esther Alonso
- Hematology Laboratory, Hospital de Bellvitge, Hospitalet de Llobregat (Barcelona), Spain
| | - Esmeralda de la Banda
- Hematology Laboratory, Hospital de Bellvitge, Hospitalet de Llobregat (Barcelona), Spain
| | - Inés Rodríguez-Hernández
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Josep Maria Ribera
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| | - Fuensanta Millá
- Hematology Laboratory/Service, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut Josep Carreras, Badalona (Barcelona), Spain
| |
Collapse
|
28
|
Sorigue M, Sancho JM, Morgades M, Moreno M, Grífols JR, Alonso E, Juncà J, Ferrà C, Batlle M, Vives S, Motlló C, García-Caro M, Navarro JT, Millà F, Feliu E, Ribera JM. Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. Leuk Lymphoma 2016; 58:916-922. [PMID: 27561733 DOI: 10.1080/10428194.2016.1222378] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
It is unclear whether higher CD34 + cell doses infused for ASCT have any influence on survival or relapse in patients with lymphoma. We analyzed the correlation of infused CD34 + cell dose with relapse, survival, and hematopoietic recovery in 146 consecutive patients undergoing ASCT for lymphoma. Higher doses (>5 × 106/kg) were significantly correlated with earlier hematopoietic recovery, fewer infectious episodes, lower transfusion needs. No differences were observed in lymphoma outcomes (4-year relapse incidence of 38% [95%CI: 29%-48%] in the lower dose group versus 51% [95%CI: 30%-69%] in the higher dose group, 10-year OS probabilities of 58% [95%CI: 48%-68%] versus 75% [95%CI: 59%-91%], 10-year DFS probabilities of 47% [95%CI: 37%-57%] versus 42% [95%CI: 23%-61%], p = NS for all outcomes). In this series, a higher infused CD34 + cell dose did not correlate with survival or relapse but correlated with earlier hematopoietic recovery and lower resource consumption.
Collapse
Affiliation(s)
- Marc Sorigue
- a Department of Hematology , Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Juan-Manuel Sancho
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Mireia Morgades
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Miriam Moreno
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Juan-Ramon Grífols
- c Banc de Sang i Teixits, Hospital Germans Trias i Pujol , Badalona , Spain
| | - Eva Alonso
- c Banc de Sang i Teixits, Hospital Germans Trias i Pujol , Badalona , Spain
| | - Jordi Juncà
- d Department of Laboratory Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Christelle Ferrà
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Montserrat Batlle
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Susana Vives
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Cristina Motlló
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Montserrat García-Caro
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Jose-Tomás Navarro
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Fuensanta Millà
- d Department of Laboratory Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Evarist Feliu
- d Department of Laboratory Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras , Universitat Autònoma de Barcelona , Badalona , Spain
| | - Josep-María Ribera
- b Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute , Universitat Autònoma de Barcelona , Badalona , Spain
| |
Collapse
|
29
|
Sorigué M, Juncà J, Marcé S, Cabezón M, García O, Zamora L. The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies. Leuk Lymphoma 2015; 57:244-6. [PMID: 25956041 DOI: 10.3109/10428194.2015.1046865] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Marc Sorigué
- a Department of Hematology , ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Jordi Juncà
- b Josep Carreras Leukemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Silvia Marcé
- b Josep Carreras Leukemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Marta Cabezón
- b Josep Carreras Leukemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Olga García
- b Josep Carreras Leukemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| | - Lurdes Zamora
- b Josep Carreras Leukemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona , Badalona , Spain
| |
Collapse
|
30
|
Sorigué M, Juncà J, Sancho JM, Morgades M, Esteban D, Navarro JT, Vives S, Feliu E, Ribera JM. Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. Leuk Lymphoma 2015; 56:2190-2. [PMID: 25641427 DOI: 10.3109/10428194.2014.996752] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Marc Sorigué
- Department of Hematology, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona , Badalona , Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Britos-Franco P, Rodríguez-Hernández I, Navarro JT, Granada I, Tapia G, Juncà J, Ribera JM, Millá F. Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases. Leuk Lymphoma 2014; 56:789-92. [PMID: 24884313 DOI: 10.3109/10428194.2014.928932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Perla Britos-Franco
- Department of Hematology, Germans Trias i Pujol Hospital , Barcelona , Spain
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Juncà J, Botín T, Rodríguez-Hernández I, Millá F, Dong HY, Kung JX, Bhardwaj V. CD11b expression in acute promyelocytic leukemia. Am J Clin Pathol 2014; 141:900. [PMID: 24838339 DOI: 10.1309/ajcpaorg0m1dprwd] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Affiliation(s)
- Jordi Juncà
- Hematology Laboratory, Institut Català d’Oncologia, IJC, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Teresa Botín
- Hematology Laboratory, Institut Català d’Oncologia, IJC, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Inés Rodríguez-Hernández
- Hematology Laboratory, Institut Català d’Oncologia, IJC, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Fuensanta Millá
- Hematology Laboratory, Institut Català d’Oncologia, IJC, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | | | | |
Collapse
|
33
|
Sorigue M, Juncà J, Gassiot S, Millá F, Mate JL, Navarro JT. A case of CD138−/CD19+/CD4+ IgD plasma cell leukemia. Cytometry 2014; 88:69-73. [DOI: 10.1002/cyto.b.21173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/12/2014] [Accepted: 03/14/2014] [Indexed: 12/18/2022]
Affiliation(s)
- Marc Sorigue
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| | - Jordi Juncà
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| | - Susanna Gassiot
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| | - Fuensanta Millá
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| | - José-Luis Mate
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| | - Josep Tomàs Navarro
- IJC, Hospital Germans Trias i Pujol, Hematology Laboratory and Pathology Service; Badalona Spain
| |
Collapse
|
34
|
Sorigue M, Juncà J, Gassiot S, Millá F, Mate JL, Navarro JT. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. Cytometry B Clin Cytom 2014:n/a-n/a. [PMID: 24659135 DOI: 10.1002/cytob.21173] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Revised: 03/12/2014] [Accepted: 03/14/2014] [Indexed: 11/06/2022]
Abstract
Background: Plasma cell leukemia (PCL) is an uncommon and aggressive disease caused by the clonal proliferation of atypical plasma cells with phenotypical abnormalities similar to those seen in multiple myeloma (MM), although at different rates. Here we report a case of IgD PCL with a very unusual CD138-/CD19+/CD4+ phenotype Methods: Peripheral blood and bone marrow samples from a 37 year old patient afflicted by an aggressive plasma cell dyscrasia were examined and analyzed by conventional morphology, flow cytometry and immunohistochemistry. Results: Analysis of peripheral blood fulfilled criteria for PCL (more than 20% and more than 2x10e9 cells/L). However, flow cytometry and immunohistochemistry phenotyping revealed that the cells were CD138-/CD38+/CD19+/CD4+/CD56-/CD117- Conclusion: PCL is diagnosed on peripheral blood smear. Immunophenotyping is a tool that can be helpful in diagnosing difficult cases but its atypical findings should not prevent the appropriate PCL diagnosis in clinically and morphologically unquestionable cases. © 2014 Clinical Cytometry Society.
Collapse
|
35
|
Fernandez-Sojo J, Navarro JT, Vives-Polo S, Juncà J. Hemólisis intravascular por Clostridium perfringens. Med Clin (Barc) 2014; 142:e1. [DOI: 10.1016/j.medcli.2013.05.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2013] [Revised: 05/18/2013] [Accepted: 05/22/2013] [Indexed: 11/27/2022]
|
36
|
Motlló C, Sancho JM, Grífols JR, Juncà J, Morgades M, Ester A, Rodríguez I, Vives S, Batlle M, Guardia R, Ferrà C, Gallardo D, Millá F, Feliu E, Ribera JM. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy 2013; 16:406-11. [PMID: 24176544 DOI: 10.1016/j.jcyt.2013.08.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Revised: 07/31/2013] [Accepted: 08/10/2013] [Indexed: 11/24/2022]
Abstract
BACKGROUND AIMS The increasing scarcity of young related donors has led to the use of older donors for related allogeneic hematopoietic stem cell transplantation (HSCT). This study analyzed the influence of age on the results of mobilization of peripheral blood stem cells (PBSCs) in healthy donors as well as on the engraftment and outcome of HSCT. METHODS A retrospective analysis from a single center was performed comparing the results of PBSC mobilization from related healthy donors according to their age. RESULTS The study included 133 consecutive related donors. The median age was 50 years (range, 4-77 years); 70 (53%) donors were males, and 44 (33%) were >55 years old. All donors were mobilized with granulocyte colony-stimulating factor for 5 days. The peak CD34(+) cell count in peripheral blood was higher in younger than in older donors (median, 90.5 CD34(+) cells/μL [range, 18-240 CD34(+) cells/μL] versus 72 CD34(+) cells/μL [range, 20-172.5 CD34(+) cells/μL], P = 0.008). The volume processed was lower in younger than in older donors (16,131 mL [range, 4424-36,906 mL] versus 18,653 mL [range, 10,003-26,261 mL], P = 0.002) with similar CD34(+) cells collected (579.3 × 10(6) cells [range, 135.14 × 10(6)-1557.24 × 10(6) cells] versus 513.69 × 10(6) cells [range, 149.81 × 10(6)-1290 × 10(6) cells], P = 0.844). There were no differences in time to recovery of neutrophils and platelets or in the incidences of acute and chronic graft-versus-host disease, overall survival, non-relapse mortality and relapse incidence. CONCLUSIONS Donors >55 years old mobilized fewer CD34(+) cells and required a greater volume to collect a similar number of CD34(+) cells. The outcome of HSCT was not influenced by donor age. Donor age should not be a limitation for related allogeneic HSCT.
Collapse
Affiliation(s)
- Cristina Motlló
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
| | - Juan-Manuel Sancho
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | | | - Jordi Juncà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Mireia Morgades
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Anna Ester
- Banc de Sang i Teixits, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Inés Rodríguez
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Susana Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Montserrat Batlle
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Ramon Guardia
- Clinical Hematology Department, ICO-Hospital Josep Trueta, Girona, Spain
| | - Christelle Ferrà
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - David Gallardo
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Fuensanta Millá
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Evarist Feliu
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Josep-Maria Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| |
Collapse
|
37
|
Juncà J, Botín T, Vila J, Navarro JT, Millá F. Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype. Cytometry B Clin Cytom 2013; 86:292-6. [PMID: 24115371 DOI: 10.1002/cyto.b.21130] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Revised: 08/13/2013] [Accepted: 08/27/2013] [Indexed: 11/12/2022]
Abstract
BACKGROUND Acute T-cell leukemia lymphoma (ATLL) tumor cells generally express CD2/CD3/CD5, but lack CD7. These T cells are usually CD4+CD8- and strongly express CD25, although some variability in this basic pattern may be found. Here we report a case with a very unusual CD1a positive phenotype. METHODS Samples from peripheral blood, bone marrow aspirate, lymph node, and cerebrospinal fluid obtained from a 45-year-old male patient with a T-cell lymphoproliferative disorder were immunophenotyped by multiparametric flow cytometry. Analysis of HTLV-I genome integration in tumoral cells was performed by PCR. RESULTS Neoplastic T cells were cCD3, CD2/CD5/CD30/CD25, and CD1a positive, but CD3/CD7/CD4/CD8/CD34/CD10/TdT negative. Serology and integration of HTLV-I were positive. CONCLUSION To the best of our knowledge, CD1a expression has not been previously described in this entity. Its detection raised the differential diagnosis with acute T lymphoblastic leukemia. The rest of the phenotypic markers, the morphology of the neoplastic cells, and the demonstration of HTLV-I genome integration provided the final diagnosis.
Collapse
Affiliation(s)
- Jordi Juncà
- IJC, Hematology Laboratory, ICO, Hospital Germans Trias i Pujol. Badalona, (Barcelona), Spain
| | | | | | | | | |
Collapse
|
38
|
Juncà J, Botín T, Vila J, Navarro JT, Millá F. Adult T-cell leukemia/lymphoma with an unusual CD1a positive phenotype. Cytometry B Clin Cytom 2013:n/a-n/a. [PMID: 24000197 DOI: 10.1002/cytob.21130] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Revised: 08/13/2013] [Accepted: 08/27/2013] [Indexed: 11/12/2022]
Abstract
Background: Acute T-cell leukemia lymphoma (ATLL) tumor cells generally express CD2/CD3/CD5, but lack CD7. These T cells are usually CD4+CD8- and strongly express CD25, although some variability in this basic pattern may be found. Here we report a case with a very unusual CD1a positive phenotype. Methods: Samples from peripheral blood, bone marrow aspirate, lymph node and CSF obtained from a 45 year old male patient with a T-cell lymphoproliferative disorder were immunophenotyped by multiparametric flow cytometry Analysis of HTLV-I genome integration in tumoral cells was performed by PCR. Results: Neoplastic T cells were cCD3, CD2/CD5/CD30/CD25 and CD1a positive, but CD3/CD7/CD4/CD8/CD34/CD10/TdT negative. Serology and integration of HTLV-I were positive. Conclusion: To the best of our knowledge CD1a expression has not been previously described in this entity. Its detection raised the differential diagnosis with acute T lymphoblastic leukemia. The rest of the phenotypic markers, the morphology of the neoplastic cells, and the demonstration of HTLV-I genome integration provided the final diagnosis. © 2013 Clinical Cytometry Society.
Collapse
Affiliation(s)
- Jordi Juncà
- IJC, Hematology Laboratory, ICO, Hospital Germans, Trias i Pujol, Badalona (Barcelona), Spain
| | | | | | | | | |
Collapse
|
39
|
Ribera J, Zamora L, Juncà J, Rodríguez I, Marcé S, Cabezón M, Millá F. Usefulness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. Cytometry 2013; 86:25-31. [DOI: 10.1002/cyto.b.21118] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 06/28/2013] [Accepted: 07/12/2013] [Indexed: 11/11/2022]
Affiliation(s)
- Jordi Ribera
- IJC-Institut de Recerca Contra la Leucèmia Josep Carreras; Universitat Autónoma de Barcelona
| | - Lurdes Zamora
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| | - Jordi Juncà
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| | - Inés Rodríguez
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| | - Silvia Marcé
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| | - Marta Cabezón
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| | - Fuensanta Millá
- IJC-ICO Badalona; Hospital Germans Trias i Pujol; Universitat Autónoma de Barcelona
| |
Collapse
|
40
|
Ribera J, Zamora L, Juncà J, Rodríguez I, Marcé S, Cabezón M, Millá F. Usefullness of IGH/TCR PCR studies in lymphoproliferative disorders with inconclusive clonality by flow cytometry. Cytometry B Clin Cytom 2013:n/a-n/a. [PMID: 23894019 DOI: 10.1002/cytob.21118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 06/28/2013] [Accepted: 07/12/2013] [Indexed: 11/10/2022]
Abstract
In up to 5-15% of studies of lymphoproliferative disorders (LPD) flow cytometry (FCM) or immunomorphologic methods cannot discriminate malignant from reactive processes. The aim of this work was to determine the usefulness of PCR for solving these diagnostic uncertainties. We analyzed IGH and TCRγ genes by PCR in 106 samples with inconclusive FCM results. A clonal result was registered in 36/106 studies, with a LPD being confirmed in 27 (75%) of these cases. Specifically, 9/9 IGH clonal and 16/25 TCRγ clonal results were finally diagnosed with LPD. Additionally, 2 clonal TCRγ samples with suspicion of undefined LPD were finally diagnosed with T LPD. Although polyclonal results were obtained in 47 of the cases studied (38 IGH and 9 TCRγ), hematologic neoplasms were diagnosed in 4/38 IGH polyclonal and in 1/9 TCRγ polyclonal studies. There were also 14 PCR polyclonal results (4 IGH, 10 TCRγ), albeit non-conclusive. Of these, 2/4 were eventually diagnosed with B-cell lymphoma and 3/10 with T-cell LPD. In 8 IGH samples the results of PCR techniques were non-informative but in 3/8 cases a B lymphoma was finally confirmed. We concluded that PCR is a useful technique to identify LPD when FCM is inconclusive. A PCR clonal B result is indicative of malignancy but IGH polyclonal and non-conclusive results do not exclude lymphoid neoplasms. Interpretation of T-cell clonality should be based on all the available clinical and analytical data. © 2013 Clinical Cytometry Society.
Collapse
Affiliation(s)
- Jordi Ribera
- IJC-Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autónoma de Barcelona
| | | | | | | | | | | | | |
Collapse
|
41
|
Tapia G, Mate JL, Fuente MJ, Navarro JT, Fernández-Figueras MT, Juncà J, Ferrándiz C, Ariza A. Cutaneous presentation of chronic lymphocytic leukemia as unique extramedullar involvement in a patient with normal peripheral blood lymphocyte count (monoclonal B-cell lymphocytosis). J Cutan Pathol 2013; 40:740-4. [PMID: 23639136 DOI: 10.1111/cup.12167] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Revised: 07/26/2011] [Accepted: 06/16/2012] [Indexed: 11/30/2022]
Abstract
Skin infiltration by chronic lymphocytic leukemia (CLL) is very rare and almost all reported cases occur in advanced stage. We report a patient with no relevant past medical history who presented with cutaneous erythematous plaques. A punch biopsy showed typical CLL morphologic and immunophenotypic features. Subsequent studies revealed a normal lymphocyte count in peripheral blood, and there was no evidence of lymphadenopathy or organomegaly. Flow cytometry demonstrated a clonal B-cell population both in the bone marrow and peripheral blood (1.60 × 10(9)/l) with a CLL phenotype, but it did not fulfill required criteria for CLL diagnosis. Without cutaneous involvement, this case should be classified as monoclonal B-cell lymphocytosis.
Collapse
Affiliation(s)
- Gustavo Tapia
- Department of Pathology, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Juncà J, Millá F, Xicoy B, García-Caro M, Rodríguez-Hernández I, Aróstegui JI. Pro-B acute lymphoblastic leukemia in a patient with severe congenital neutropenia: an unusual form of malignant evolution. Leuk Lymphoma 2013; 54:2325-7. [DOI: 10.3109/10428194.2013.773999] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
43
|
Vives S, Sancho JM, Almazán F, Juncà J, Grifols JR, Ribera JM. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. J Clin Apher 2012; 27:260-2. [PMID: 22566276 DOI: 10.1002/jca.21234] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Accepted: 03/31/2012] [Indexed: 12/30/2022]
Abstract
Some malignant tumors in childhood require high-dose chemotherapy with stem cell support to achieve a cure. In patients heavily pretreated with myelosuppressive chemotherapy or irradiation, granulocyte colony-stimulating factor (G-CSF) may fail to mobilize stem cells from the bone marrow. Based on the experience with lymphoma and myeloma patients in whom peripheral blood-derived stem cell (PBSC) collection following mobilization with G-CSF failed, we successfully employed plerixafor in a 14-year-old female diagnosed with Ewing's sarcoma in early relapse treated with three lines of chemotherapy in whom PBSC could not be mobilized using either G-CSF alone or G-CSF following chemotherapy. No side effects were observed. Plerixafor may be an effective and safe agent for stem cell collection in pediatric patients with solid tumors, although new studies addressed to evaluate its effectiveness and safety are needed.
Collapse
Affiliation(s)
- Susana Vives
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol Badalona, Jose Carreras Leukemia Research Institute, Universitat Autonòma of Barcelona, Badalona, Spain.
| | | | | | | | | | | |
Collapse
|
44
|
Sancho JM, Morgades M, Grifols JR, Juncà J, Guardia R, Vives S, Ferrà C, Batlle M, Ester A, Gallardo D, Millà F, Feliu E, Ribera JM. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012; 14:823-9. [PMID: 22540329 DOI: 10.3109/14653249.2012.681042] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND AIMS Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the administration of pre-emptive rescue mobilization. METHODS Data from the first mobilization schedule of 397 patients referred consecutively for autologous HSCT between 2000 and 2010 were collected. Poor mobilization was defined as the collection of < 2 × 10(6) CD34(+)cells/kg body weight (BW). RESULTS The median age was 53 years (range 4-70) and 228 (57%) were males. Diagnoses were multiple myeloma in 133 cases, non-Hodgkin's lymphoma in 114, acute myeloid leukemia or myelodysplastic syndrome in 81, Hodgkin's lymphoma in 42, solid tumors in 17 and acute lymphoblastic leukemia in 10. The mobilization regimen consisted of recombinant human granulocyte-colony-stimulating factor (G-CSF) in 346 patients (87%) and chemotherapy followed by G-CSF (C + G-CSF) in 51 (13%). Poor mobilization occurred in 105 patients (29%), without differences according to mobilization schedule. Diagnosis, previous therapy with purine analogs and three or more previous chemotherapy lines were predictive factors for poor mobilization. A CD34(+)cell count in PB > 13.8/μL was enough to ensure ≥ 2 × 10(6) CD34(+)cells/kg, with high sensitivity (90%) and specificity (91%). CONCLUSIONS The prevalence of poor mobilization was high, being associated with disease type, therapy with purine analogs and multiple chemotherapy regimens. The threshold of CD34(+) cell count in PB identified poor mobilizers, in whom the administration of immediate or pre-emptive plerixafor could be useful to avoid a second mobilization.
Collapse
Affiliation(s)
- Juan-Manuel Sancho
- Clinical Hematology Department, ICO-Hospital Universitari Germans Trias i Pujol, José Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Juncà J, Ruiz-Xivillé N, Granada I, Rodríguez-Hernández I, Navarro JT, Mate JL, Millá F. Scoring systems in mantle cell lymphoma: a critical point of view. Cytometry B Clin Cytom 2011; 82:120-2. [PMID: 21915995 DOI: 10.1002/cyto.b.20620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2011] [Revised: 08/10/2011] [Accepted: 08/11/2011] [Indexed: 11/10/2022]
Abstract
A proposal for a scoring system in the diagnosis of chronic lymphoproliferative diseases other than CLL has been recently published in Cytometry Part B. The authors apply this score for deciding whether or not FISH evaluation for the detection of IGH/CCND1 rearrangements must be performed to exclude Mantle Cell Lymphoma (MCL). In their validation series, no MCL scored <3. We have applied their system to our cases of MCL and also to a small series of Marginal Zone lymphomas. In our hands, the scoring system as has been published does not discriminate adequately between both entities. We propose using the negativity of a marker, CD11c, instead of the platelet count to improve the results. However, we believe that given the clinical and prognostic implications of the diagnosis of MCL, scoring systems should be greatly ameliorated prior to their generalized use.
Collapse
Affiliation(s)
- Jordi Juncà
- Hematology Laboratory, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
| | | | | | | | | | | | | |
Collapse
|
46
|
Pérez-Montaña A, Navarro JT, Juncà J, Ribera JM. [Spontaneous complete remission in two patients with chronic lymphocytic leukemia]. Med Clin (Barc) 2011; 137:238-9. [PMID: 21146841 DOI: 10.1016/j.medcli.2010.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2010] [Accepted: 09/16/2010] [Indexed: 11/17/2022]
|
47
|
Alonso N, Granada ML, Soldevila B, Salinas I, Joaquin C, Reverter JL, Juncà J, Martínez Cáceres EM, Sanmartí A. Serum autoimmune gastritis markers, pepsinogen I and parietal cell antibodies, in patients with type 1 diabetes mellitus: a 5-year prospective study. J Endocrinol Invest 2011; 34:340-4. [PMID: 20530988 DOI: 10.1007/bf03347456] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND AND AIM To determine the temporal evolution of serum markers of autoimmune gastritis, mainly pepsinogen I (PI) and parietal cell antibodies (PCA), in patients with Type 1 diabetes mellitus (DM1). MATERIALS AND METHODS A 5-yr prospective follow-up study of 168 DM1 patients (87 men, aged 31 ± 9.3 yr) attending the endocrinology outpatient clinic of a university hospital evaluated in 2001 and 2006. Serum PI, gastrin, hemoglobin, cobalamin concentrations, PCA and antibodies to intrinsic factor were measured. RESULTS In 2001, 11 patients had low PI concentrations and positive PCA (group I), 11 had only low PI concentrations (group II), and 33 had only positive PCA (group III). After 5 yr, PI remained low and PCA positive in all patients from group I. In group II, PI remained low in 4 and normalized in 7. In group III, 4 patients presented low PI concentrations after 5 yr, which remained normal in the other 29 subjects. PCA became negative in 17 patients from group III. In 2001, 3 of the 11 patients of group I had low cobalamin concentrations. In 2006, 2 additional patients from this group presented low cobalamin concentrations. CONCLUSIONS These results show the importance of determining PI together with PCA, since the presence of abnormal results in both tests, that is low PI and positive PCA, is the association that best identifies patients with a higher risk to decrease cobalamin concentrations during follow-up.
Collapse
Affiliation(s)
- N Alonso
- Department of Endocrinology and Nutrition, Autonomous University of Barcelona, Hospital Universitari Germans Trias i Pujol, Ctra Canyet s/n, Badalona 08916, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Motlló C, Grau J, Juncà J, Ruiz N, Mate JL, Orna E, Navarro JT, Vives S, Sancho JM, Esteban D, Granada I, Feliu E, Ribera JM, Millá F. Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. ACTA ACUST UNITED AC 2010; 203:328-32. [DOI: 10.1016/j.cancergencyto.2010.08.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2010] [Revised: 08/11/2010] [Accepted: 08/14/2010] [Indexed: 10/18/2022]
|
49
|
Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M, Estivill C, Queipo MP, Guardia R, Carricondo M, Hoyos M, Llorente A, Juncà J, Gallart M, Domingo A, Bargay J, Mascaró M, Moraleda JM, Florensa L, Ribera JM, Gallardo D, Brunet S, Aventin A, Sierra J. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res 2010; 35:163-8. [PMID: 20542566 DOI: 10.1016/j.leukres.2010.05.015] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2010] [Revised: 05/12/2010] [Accepted: 05/17/2010] [Indexed: 11/26/2022]
Abstract
NPM mutations are the most common genetic abnormalities found in non-promyelocytic AML. NPM-positive patients usually show a normal karyotype, a peculiar morphologic appearance with frequent monocytic traits and good prognosis in the absence of an associated FLT3 mutation. This report describes the immunophenotypic and genetic characteristics of a consecutive series of NPM-mutated de novo AML patients enroled in the CETLAM trial. Eighty-three patients were included in the study. Complete immunophenotype was obtained using multiparametric flow cytometry. Associated genetic lesions (FLT3, MLL, CEBPA and WT1 mutations) were studied by standardized methods. Real-time PCR was employed to assess the minimal residual status. The most common pattern was CD34-CD15+ and HLA-DR+. Small CD34 populations with immunophenotypic aberrations (CD15 and CD19 coexpression, abnormal SSC) were detected even in CD34 negative samples. Nearly all cases expressed CD33 (strong positivity), CD13 and CD117, and all were CD123+. The stem cell marker CD110 was also positive in most cases. Biologic parameters such as a high percentage of intermediate CD45+ (blast gate) (>75% nucleated cells), CD123+ and FLT3-ITD mutations were associated with a poor outcome. Quantitative PCR positivity had no prognostic impact either after induction or at the end of chemotherapy. Only PCR positivity (greater than 10 copies) detected in patients in haematological remission was associated with an increased relapse rate. Further studies are required to determine whether the degree of leukemic stem cell expansion (CD45+CD123+cells) increases the risk of acquisition of FLT3-ITD and/or provides selective advantages.
Collapse
Affiliation(s)
- J Nomdedeu
- Department of Hematology and Laboratory, Hospital de la Santa Creu I Sant Pau, Avda Sant Antoni M Claret 167, 08025 Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Juncà J, Moreno M, Mate JL, Milla F. Diagnóstico simultáneo de una leucemia aguda mieloide y un síndrome linfoproliferativo crónico, con amiloidosis AA como episodio final. Med Clin (Barc) 2010; 135:136-7. [DOI: 10.1016/j.medcli.2009.04.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2009] [Accepted: 04/14/2009] [Indexed: 11/27/2022]
|